Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

towa pharmaceutical co., ltd. - lincomycin hydrochloride hydrate - injection

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

south yarra pharma pty ltd - lincomycin hydrochloride - oral powder, pre-mix - lincomycin hydrochloride antibiotic active 1000.0 g/kg - antibiotic & related

Philippines - English - FDA (Food And Drug Administration)

rnsv corporation.; distributor: rnsv corporation. - lincomycin , spectinomycin , bromhexine (vet.) - solution for injection (im) - formulation: each ml contains: lincomycin.. (equivalent to 50 mg lincomycin hydrochloride) spectinomycin.. (equivalent to 100 mg spectinomycin sulfate) bromhexine... (equivalent to 2.5 mg bromhexine hydrochloride) 45.9 mg .77.2 mg 2.3 mg lincomycin + spectinomycin +

United States - English - NLM (National Library of Medicine)

zoetis inc. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincocin products are indicated in infections caused by gram-positive organisms which are sensitive to its action, particularly streptococci and staphylococci. the drug has proven effective in eradicating causative organisms in most of the common upper respiratory tract infections, in septicemia, and in infections of the skin and adjoining tissues. systemic therapy with lincocin has been shown to be of benefit in many animals with pustular dermatitis. as with all antibiotics, in vitro sensitivity studies should be performed before lincocin is utilized as sole antibiotic therapy. lincocin has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and sensitive to lincomycin. the drug may be administered in combination therapy with other antimicrobial agents when indicated. no serious hypersensitivity reactions have been reported and many animals have received lincocin repeatedly without developing evidence of hypersensitivity. lincocin has demonstrated e

Ireland - English - HPRA (Health Products Regulatory Authority)

huvepharma nv - lincomycin hydrochloride monohydrate; spectinomycin sulfate tetrahydrate - powder for use in drinking water - lincomycin, combinations

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - lincomycin - oral powder, pre-mix - lincomycin antibiotic active 44.0 g/kg - antibiotic & related - pigs | boar | gilt | piglet | sow | swine - antibiotic - anti-infective | abrasions | abscesses | airsacculitis | antiseptic | avian mycoplasmas | blackhead | body odours | bowed tendons | broad spectrum | burns | coccidiosis | coliform complex | conjunctivitis | cowpox | cracks | crusts | dandruff | dermatological disorders | dermatosis | dry skin | dysentery | eczema | endometritis | enteric diseases | enzootic pneumonia | feed efficiency | fungal infections | girth galls | infections | inflammed pads | itching | keratolytic | lacerations | mastitis | mycoplasmas | odours | open wounds | otitis | pruritis | queensland itch | respiratory disease | saddle rash | salmonellosis | scabs | scaly skin | sheath rot | skin irritations | sores | swine dysentery | teat cracking | teat infections | topical infections | udder sores | weight gain | wire cuts | wounds

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - lincomycin as lincomycin hydrochloride; spectinomycin as spectinomycin sulfate - oral powder, pre-mix - lincomycin as lincomycin hydrochloride antibiotic active 22.0 g/kg; spectinomycin as spectinomycin sulfate antibiotic active 22.0 g/kg - nutrition & metabolism - pigs | boar | gilt | piglet | sow | swine - bloody scours | enteritis associated with e.coli | mycoplasmal pneumonia | promote animal growth | salmonellosis | vibrionic dysentery | feed conversion | finishing | growth promotion | growth rate | liveweight gain | swine dysentery

Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle pharmaceuticals manufacturing limited - lincomycin hydrochloride; spectinomycin sulfate tetrahydrate - solution for injection - 50, 100 milligram(s)/millilitre - lincomycin, combinations - cats, cattle, dogs, pigs - antibacterial

United States - English - NLM (National Library of Medicine)

proficient rx lp - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 300 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be re‑served for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of co‑li‑tis, as described in the warning box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endomet

United States - English - NLM (National Library of Medicine)

kaiser foundation hospitals - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin 150 mg - clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be re­served for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of co­li­tis, as described in the  warning box, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endome